Jennison Associates LLC Purchases Shares of 229,704 Celcuity, Inc. $CELC

Key Points

• Jennison Associates LLC bought 229,704 shares of Celcuity in Q4 — a stake worth about $22.9 million that represents roughly 0.50% of the company, while institutional investors collectively own about 63.33% of CELC.
• Analysts are broadly positive: ten rate CELC a Buy, one a Hold and one a Sell, producing a consensus "Moderate Buy" rating with a mean target price of $114.33 (individual targets up to $150).
• Celcuity reported quarterly EPS of ($0.97), beating estimates by $0.09, and its shares have climbed from a 1‑year low of $9.51 to a 1‑year high of $129.09 with a market cap near $6.07 billion.

Jennison Associates LLC purchased a new stake in Celcuity, Inc. (NASDAQ:CELC - Free Report) during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 229,704 shares of the company's stock, valued at approximately $22,911,000. Jennison Associates LLC owned approximately 0.50% of Celcuity as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors have also recently bought and sold shares of the stock. Ogorek Anthony Joseph NY ADV lifted its stake in Celcuity by 19.7% in the fourth quarter. Ogorek Anthony Joseph NY ADV now owns 662 shares of the company's stock valued at $66,000 after buying an additional 109 shares in the last quarter. US Bancorp DE lifted its position in shares of Celcuity by 25.4% in the third quarter. US Bancorp DE now owns 706 shares of the company's stock worth $35,000 after purchasing an additional 143 shares in the last quarter. Rhumbline Advisers lifted its position in shares of Celcuity by 1.2% in the second quarter. Rhumbline Advisers now owns 42,697 shares of the company's stock worth $570,000 after purchasing an additional 503 shares in the last quarter. M&T Bank Corp lifted its position in shares of Celcuity by 14.3% in the fourth quarter. M&T Bank Corp now owns 4,671 shares of the company's stock worth $465,000 after purchasing an additional 583 shares in the last quarter. Finally, NBC Securities Inc. bought a new stake in shares of Celcuity in the fourth quarter worth $99,000. Institutional investors own 63.33% of the company's stock.

Analyst Ratings Changes

A number of analysts have recently commented on the stock. Needham & Company LLC reissued a "buy" rating and issued a $122.00 price objective on shares of Celcuity in a research report on Thursday, March 26th. Citizens Jmp assumed coverage on shares of Celcuity in a research report on Monday, April 27th. They issued a "market outperform" rating and a $150.00 price objective on the stock. Wolfe Research reissued an "outperform" rating and issued a $110.00 price objective on shares of Celcuity in a research report on Thursday, March 12th. Wall Street Zen lowered shares of Celcuity from a "hold" rating to a "sell" rating in a research report on Saturday, April 25th. Finally, Weiss Ratings reissued a "sell (d-)" rating on shares of Celcuity in a research report on Monday, April 20th. Ten equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, Celcuity has an average rating of "Moderate Buy" and a consensus target price of $114.33.

Insiders Place Their Bets

In related news, Director Richard E. Buller sold 3,000 shares of the business's stock in a transaction on Tuesday, March 31st. The shares were sold at an average price of $110.27, for a total transaction of $330,810.00. Following the transaction, the director directly owned 6,760 shares in the company, valued at approximately $745,425.20. The trade was a 30.74% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 13.33% of the company's stock.

Celcuity Price Performance

Shares of CELC opened at $125.65 on Friday. The company has a market cap of $6.07 billion, a price-to-earnings ratio of -33.15 and a beta of 0.41. Celcuity, Inc. has a 1-year low of $9.51 and a 1-year high of $129.09. The company's fifty day simple moving average is $114.53 and its 200 day simple moving average is $101.86. The company has a current ratio of 10.55, a quick ratio of 10.55 and a debt-to-equity ratio of 3.20.

Celcuity (NASDAQ:CELC - Get Free Report) last issued its earnings results on Wednesday, March 25th. The company reported ($0.97) earnings per share for the quarter, topping analysts' consensus estimates of ($1.06) by $0.09. On average, research analysts forecast that Celcuity, Inc. will post -3.97 earnings per share for the current fiscal year.

Celcuity Profile

Celcuity, Inc is a clinical-stage biotechnology company specializing in precision oncology diagnostics. The company develops and commercializes predictive biomarker assays designed to identify which patients are most likely to benefit from targeted cancer therapies. By integrating functional profiling of tumor cells with molecular analyses, Celcuity seeks to optimize treatment selection and improve outcomes for patients with solid tumors.

Celcuity’s proprietary platform evaluates tumor cell sensitivity to various therapeutic agents using ex vivo assays that measure DNA damage response and other critical pathways.

Want to see what other hedge funds are holding CELC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celcuity, Inc. (NASDAQ:CELC - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.